Pockets against pain
Amgen fills an allosteric pocket in GLRA3 to dampen neuropathic pain
Amgen Inc. (NASDAQ:AMGN) is aiming to tackle neuropathic pain by boosting glycine receptor α 3 (GLRA3) activity in the CNS. In a December study, the company presented preclinical data and crystal structures for its GLRA3 positive allosteric modulators (PAMs) that pointed to a new druggable pocket in the target.
Upon glycine binding, GLRA3